Esperion Therapeutics Inc (NASDAQ: ESPR) kicked off on Monday, up 2.28% from the previous trading day, before settling in for the closing price of $2.19. Over the past 52 weeks, ESPR has traded in a range of $1.58-$3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 7.64%. While this was happening, its average annual earnings per share was recorded 85.28%. With a float of $195.06 million, this company’s outstanding shares have now reached $195.44 million.
Let’s determine the extent of company efficiency that accounts for 240 employees. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc is 1.00%, while institutional ownership is 65.84%. The most recent insider transaction that took place on Dec 17 ’24, was worth 7,866. In this transaction Chief Financial Officer of this company sold 3,245 shares at a rate of $2.42, taking the stock ownership to the 240,691 shares. Before that another transaction happened on Dec 17 ’24, when Company’s Chief Commercial Officer sold 2,234 for $2.43, making the entire transaction worth $5,426. This insider now owns 160,121 shares in total.
Esperion Therapeutics Inc (ESPR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 85.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Take a look at Esperion Therapeutics Inc’s (ESPR) current performance indicators. Last quarter, stock had a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach 0.22 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Looking closely at Esperion Therapeutics Inc (NASDAQ: ESPR), its last 5-days average volume was 5.18 million, which is a drop from its year-to-date volume of 6.36 million. As of the previous 9 days, the stock’s Stochastic %D was 21.59%. Additionally, its Average True Range was 0.30.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 27.97%, which indicates a significant increase from 19.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 153.22% in the past 14 days, which was higher than the 90.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.41, while its 200-day Moving Average is $2.24. However, in the short run, Esperion Therapeutics Inc’s stock first resistance to watch stands at $2.29. Second resistance stands at $2.34. The third major resistance level sits at $2.39. If the price goes on to break the first support level at $2.19, it is likely to go to the next support level at $2.14. Should the price break the second support level, the third support level stands at $2.09.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
The company with the Market Capitalisation of 441.36 million has total of 197,035K Shares Outstanding. Its annual sales at the moment are 116,330 K in contrast with the sum of -209,250 K annual income. Company’s last quarter sales were recorded 51,630 K and last quarter income was -29,520 K.
